Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
17
Frequently Asked Questions
What is Market Cap of Relmada Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Relmada Therapeutics Inc market cap is $55.43M.
What is the 52-week high for Relmada Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Relmada Therapeutics Inc 52 week high is $3.98 as of September 16, 2025.
What is the 52-week low for Relmada Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Relmada Therapeutics Inc 52 week low is $0.2404 as of September 16, 2025.
What is Relmada Therapeutics Inc stock price today?
Relmada Therapeutics Inc stock price today is $1.77.
What was Relmada Therapeutics Inc stock price yesterday?
Relmada Therapeutics Inc stock price yesterday was $1.67.
What is the PE ratio of Relmada Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Relmada Therapeutics Inc’s P/E ratio is -0.75.
What is the Price-to-Book ratio of Relmada Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Relmada Therapeutics Inc P/B ratio is 3.4753.
What is the 50-day moving average of Relmada Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Relmada Therapeutics Inc 50-day moving average is $0.8186.
How many employess does Relmada Therapeutics Inc has?
